CoverageNEW YORK, NY, December 6, 2016 /Sector Newswire/ --
DIAGNOS Inc. (TSX-V: ADK) (US Listing: DGNOF) is a Canadian-based healthcare software technology company, its 'Computer Assisted Retinal Analysis' (CARA) business applies artificial intelligence in the diabetes market which non-invasively identify patients at risk of vision loss. DIAGNOS is the subject of an article by Dr. W. Gifford-Jones published by Postmedia in various venues. DIANGOS' current retinal analysis business was incepted in the wake of the downturn in the mining sector a few years back, DIAGNOS was focused on data analysis in that sector and made the decision to springboard off its platform and expertise in artificial intelligence to build the application it has now in order to fill the gap between doctors and specialists. Dr. Gifford-Jones is an accomplished doctor/surgeon and writer, he is also known for his extensive travels to interview internationally renowned scientists and researchers. Dr. Gifford-Jones took the time to visit DIAGNOS and provided his opinion in an article entitled "A miner could save millions from blindness"; the article may be viewed in its entirety at
https://www.orilliapacket.com/2016/12/05/a-miner-could-save-millions-from-blindness online.
DIAGNOS is also the subject of a Technology MarketWatch Journal review. DIAGNOS Inc. is expanding globally as a first-mover in this sector with proprietary disruptive technology whose adoption is quickly gaining momentum, doctors and specialists strongly endorse it as large numbers are non-invasively screened that would otherwise not be seen. ADK.V's revenue growth curve is rapidly accelerating with topline >100% Y/Y. Swiss pharmaceutical giant Novartis has become the Company's biggest customer, initially engaging ADK.V for a series of pilot 'wellness' programs over the last couple years in various countries, paying DIAGNOS to screen patients. Recently Novartis has begun converting pilot programs into contracts, with more on the way due to the overwhelming success in identifying patients that could benefit from Novartis' treatment. German pharmaceutical company Bayer has only recently engaged ADK.V with similar intentions. DIAGNOS recently signed a contract with an unnamed pharmaceutical company targeting the US, the world's largest healthcare market. ADK.V has also started to sell its solutions to governments on a cost-reduction approach, recently signing its first government contract in Mexico. Supported by a strong growth and recurring revenue model, and a low cost growth associated with its artificial intelligence software, we expect shares of ADK.V to rise several multiples higher than its current price near-term.
Full copy of the Technology MarketWatch Journal Review may be viewed at
https://technologymarketwatch.com/adk.htm online.